Quick Takeaways
- Kynam Capital Management, LP filed SCHEDULE 13G/A for Celldex Therapeutics, Inc. Common Stock, par value $0.001 (CLDX).
- Disclosed ownership: 9.8%.
- Date of event: 31 Mar 2025.
Kynam Capital Management, LP - 31 Mar 2025 SCHEDULE 13G/A Report for Celldex Therapeutics, Inc. Common Stock, par value $0.001 (CLDX)
- Filing Manager
- Kynam Capital Management, LP
- Reporting Manager
- Kynam Capital Management, LP
- Symbol
- CLDX
- Shares outstanding
- 66,394,280 shares
- Disclosed Ownership
- 6,500,000 shares
- Ownership
- 9.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2025, 11:48:13 UTC
- Date of event
- 31 Mar 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Kynam Capital Management, LP disclosed 9.8% ownership in Celldex Therapeutics, Inc. Common Stock, par value $0.001 (CLDX) on 31 Mar 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 15 May 2025, 11:48.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Kynam Capital Management, LP | 9.8% | 6,500,000 | 0 | 6,500,000 | Yue Tang | Managing Member | |
| Kynam Capital Management GP, LLC | 9.8% | 6,500,000 | 0 | 6,500,000 | Yue Tang | Managing Member | |
| Yue Tang | 9.8% | 6,500,000 | 0 | 6,500,000 | Yue Tang | Self |